Stockscreener 앱 받기
0.3111
7.55%
-0.0254
시장 영업 전:
.36
0.0489
+15.72%
Vaxart Inc 주식(VXRT)의 최신 뉴스
VXRT stock touches 52-week low at $0.31 amid market challenges - Investing.com India
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
RFK Jr. pauses $240 million contract for new ‘oral COVID vaccine’ - Todayville
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vaxart reports inducement grants under Nasdaq listing rule - TipRanks
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges - Investing.com
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges By Investing.com - Investing.com South Africa
Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vaxart's Major Talent Investment: 659,500 Share Awards and Key Executive Hire Signals Growth - Stock Titan
B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating - MarketScreener
Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript - Insider Monkey
Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Oral - Vaxart Inc.
Sudden Trump administration order prompts Bay Area company to lay off staff - SFGATE
Bay Area biotech company lays off staff over sudden Trump admin order - SFGATE
Vaxart Inc to offer up to $50 mln of common stock -March 21, 2025 at 04:42 pm EDT - MarketScreener
RFK Jr. paused this Peninsula company's half-billion-dollar vaccine contract, then it cut jobs - The Business Journals
Vaxart Inc Reports Q4 EPS of -$0.12, Missing Estimates; Revenue at $19.5 Million, Below Expectations - GuruFocus
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ... - Yahoo Finance
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments Amid Challenges - GuruFocus.com
Vaxart Reports 2024 Financial Results and Vaccine Progress - TipRanks
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action – VXRT - Business Wire
Earnings call transcript: Vaxart Q4 2024 misses EPS but beats revenue - Investing.com India
Vaxart Inc. (VXRT) reports earnings - Quartz
Vaxart Provides Business Update And Reports Full Year 2024 Financial Results -March 20, 2025 at 04:49 pm EDT - MarketScreener
Vaxart, Inc. SEC 10-K Report - TradingView
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewswire
Vaxart Quadruples Revenue to $28.7M as New Norovirus Vaccine Trial Launches - Stock Titan
FDA Mid-Month ID Food Recall Safety Updates - ContagionLive
Pipeline - Vaxart Inc.
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20 - GlobeNewswire
Vaxart, Inc. to Host Conference Call for Business Update and Financial Results on March 20, 2025 - Nasdaq
Vaxart's Crucial 2024 Financial Update: Management to Reveal Full-Year Performance - Stock Titan
ElectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Vaxart starts early-stage study for its pill-based vaccine for norovirus -March 11, 2025 at 08:57 am EDT - Marketscreener.com
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate - GlobeNewswire
First-Ever Norovirus Pill Vaccine Enters Clinical Trials: Vaxart's Game-Changing Approach - StockTitan
Financial Survey: Quince Therapeutics (NASDAQ:QNCX) & Vaxart (NASDAQ:VXRT) - Defense World
Our Science - Vaxart Inc.
Vaxart's Oral Norovirus Vaccine: Key Study Findings and Future Plans - Contagionlive.com
Vaxart (VXRT) Projected to Post Quarterly Earnings on Thursday - Defense World
Vaxart reports promising norovirus vaccine trial results By Investing.com - Investing.com Canada
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults - The Manila Times
Vaxart reports promising norovirus vaccine trial results - Investing.com
0.48%
자본화:
|
볼륨(24시간):